CROI 2012 Oral Presentation #95 . Probiotic Supplementation of ARV Treatment during SIV Infection of Pigtail Macaques Results in Enhanced GI Tract CD4+ T Cell Frequency and Immunological Function During progressive HIV/SIV (simian immune defficiency virus in monkeys) infections, damage to the GI tract leads to microbial translocation, which may contribute to chronic immune activation […]
Do Friendly Bugs Improve Immune Function? Read More »
Can someone with no detectable HIV virus in their blood due to successful HIV treatment infect someone? “Undetectable viral loads in blood is not a guarantee that HIV is also undetectable in semen, according to a new study involving 101 HIV-positive men who have sex with men (MSM) conducted in Boston and published online ahead of print
Have you wanted to take a vacation from your own head? You could do it easily enough with liberal applications of alcohol or hallucinogens, but that’s not the kind of vacation I’m talking about. What if you could take a very specific vacation only from the stuff that makes it painful to be you: the
How electrical brain stimulation can change the way we think Read More »
Great overview written in layman’s terms Controversies in HIV cure research Journal of the International AIDS Society 2012, 15:16 doi:10.1186/1758-2652-15-1 Rowena Johnston ([email protected]) Francoise Barre-Sinoussi ([email protected])
Controversies in HIV cure research Read More »
I highly recommend watching Dr Sharon Lewin’s talk ( first one after the introduction). In my opinion, it is the best talk I have seen on the current status of HIV cure research https://bit.ly/xpT8re
Best HIV Cure Lecture at CROI 2012 Read More »
NATAP/CROI: HIV Eradication Study by DMargolis with Cancer Drug Here is link to webcast of the oral session at CROI called HIV Persistence, Latency, and Eradication where Dr David Margolis presented the results of the study he conducted which is discussed below: https://app2.capitalreach.com/esp1204/servlet/tc?c=10164&cn=retro&s=20481&&dp=player.jsp&e=16643&mediaType=podiumVideo from Jules Levin: The drug Zolinza used in this study appears to
Getting HIV Out of its Hiding Places – Reports from CROI 2012 Read More »
Subject: NATAP/CROI: Frailty/Muscle Loss in HIV Increases Mortality & is Common NATAP https://natap.org/ _______________________________________________ Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ from Jules Levin at CROI Live in Seattle. This poster session is a breakthrough in that it is identifying that muscle loss & frailty are fairly common in HIV+ persons & they
Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ Read More »
Thanks to Siegfried Schwarze, a research activist from Germany, for writing down these notes from the meeting we had this past Sunday, March 4, 2012 in Seattle prior to CROI-2012. **************************************************************************** Sometimes the most important events don‘t take place at the conference itself but rather at the surrounding workshops. This seemed to be the case this
Pre-CROI HIV Cure Review Workshop Organized by Community Advocates- Meeting Notes Read More »
A couple of months ago a rag tag group of activist–including Project Inform (represented by myself), the Treatment Action Group (TAG) and the AIDS Treatment Activists Coalition (ATAC)–reached out to some of the world’s leading HIV researchers and companies working on HIV cure research and asked them to spend an entire day with us talking
Report of This Weekend’s HIV Cure Workshop in Seattle Read More »
The first presentation in this link shows Dr John Mellors speaking at the Conference of Retroviruses and Opportunistic Infections in Seattle on March 5, 2012. He did a great job at an overview of where we are in HIV Cure Research. HIV Reservoirs and Cure Research Lecture
HIV Reservoirs and Cure Research Lecture at CROI 2012 Read More »
The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare’s investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for
FOR IMMEDIATE RELEASE: February 9, 2012 Contact: Nelson Vergel ([email protected]) Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program New York, February 9, 2012—AIDS activists and physician advocates welcome the news that ViiV Healthcare will be providing expanded access of dolutegravir (DTG), a new investigational integrase inhibitor for HIV patients with
